The dual PI3K/mTOR-pathway inhibitor GDC-0084 achieves antitumor activity in PIK3CA-mutant breast cancer brain metastases

PURPOSE: Previous studies have shown that the PI3K/Akt/mTOR-pathway is activated in up to 70% of breast cancer brain metastases, but there are no approved agents for affected patients. GDC-0084 is a brain penetrant, dual PI3K/mTOR-inhibitor that has shown promising activity in a preclinical model of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Ippen, Franziska M., Alvarez-Breckenridge, Christopher A., Kuter, Benjamin M., Fink, Alexandria L., Bihun, Ivanna V., Lastrapes, Matthew, Penson, Tristan, Schmidt, Stephen P., Wojtkiewicz, Gregory R., Ning, Jianfang, Subramanian, Megha, Giobbie-Hurder, Anita, Martinez-Lage, Maria, Carter, Scott L., Cahill, Daniel P., Wakimoto, Hiroaki, Brastianos, Priscilla K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6685218/
https://ncbi.nlm.nih.gov/pubmed/30796030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3049
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky